IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

FDA issues warning letter to API plant in India

4:06 AM MDT | March 13, 2014 | Deepti Ramesh

FDA issued a warning letter at the end of February 2014 to the active pharmaceutical ingredient (API) manufacturing facility of Canton Laboratories (Vadodara, India) located at Vadodara for violations of cGMP. An FDA inspection from 1-9 April 2013 at the Vadodara API facility identified significant deviations from cGMP for the manufacture of APIs, FDA says. The warning letter was published in the FDA website earlier this week. The violations at the API site include failure to perform laboratory testing of APIs to ensure conformance to specifications and to...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis from the entire global chemical enterprise on chemweek.com
  • Mobile edition of Chemical Week
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional focus
  • Global outlook issue




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa